Insider Selling: Exelixis, Inc. (EXEL) EVP Sells 14,818 Shares of Stock

Exelixis, Inc. (NASDAQ:EXEL) EVP Jeffrey Hessekiel sold 14,818 shares of Exelixis stock in a transaction on Friday, November 30th. The shares were sold at an average price of $19.25, for a total transaction of $285,246.50. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Jeffrey Hessekiel also recently made the following trade(s):

  • On Wednesday, November 28th, Jeffrey Hessekiel sold 11,759 shares of Exelixis stock. The shares were sold at an average price of $19.12, for a total transaction of $224,832.08.

EXEL opened at $20.31 on Friday. The stock has a market capitalization of $6.07 billion, a PE ratio of 17.21, a P/E/G ratio of 1.20 and a beta of 2.29. Exelixis, Inc. has a 1-year low of $13.42 and a 1-year high of $32.20. The company has a quick ratio of 8.54, a current ratio of 8.66 and a debt-to-equity ratio of 0.01.

Exelixis (NASDAQ:EXEL) last released its earnings results on Thursday, November 1st. The biotechnology company reported $0.41 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.19 by $0.22. The company had revenue of $225.40 million during the quarter, compared to the consensus estimate of $174.14 million. Exelixis had a net margin of 49.53% and a return on equity of 55.71%. The company’s revenue was up 47.8% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.26 EPS. On average, equities analysts expect that Exelixis, Inc. will post 1.3 EPS for the current year.

EXEL has been the topic of several recent research reports. Morgan Stanley initiated coverage on shares of Exelixis in a report on Monday, September 10th. They set an “underweight” rating and a $19.00 target price on the stock. Goldman Sachs Group started coverage on shares of Exelixis in a report on Monday, September 17th. They issued a “neutral” rating and a $22.00 price objective on the stock. BidaskClub upgraded shares of Exelixis from a “strong sell” rating to a “sell” rating in a report on Saturday, September 29th. Piper Jaffray Companies cut their price objective on shares of Exelixis from $29.00 to $26.00 and set an “overweight” rating on the stock in a report on Monday, November 5th. Finally, Oppenheimer set a $40.00 price objective on shares of Exelixis and gave the stock a “buy” rating in a report on Thursday, November 15th. Two equities research analysts have rated the stock with a sell rating, three have issued a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. The stock has an average rating of “Buy” and a consensus target price of $29.44.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC increased its position in shares of Exelixis by 31.2% in the 2nd quarter. Janney Montgomery Scott LLC now owns 17,220 shares of the biotechnology company’s stock worth $371,000 after purchasing an additional 4,095 shares during the last quarter. American Century Companies Inc. increased its position in shares of Exelixis by 504.6% in the 2nd quarter. American Century Companies Inc. now owns 2,034,270 shares of the biotechnology company’s stock worth $43,777,000 after purchasing an additional 1,697,822 shares during the last quarter. First Trust Advisors LP increased its position in shares of Exelixis by 78.6% in the 3rd quarter. First Trust Advisors LP now owns 4,643,726 shares of the biotechnology company’s stock worth $82,287,000 after purchasing an additional 2,044,201 shares during the last quarter. Schwab Charles Investment Management Inc. increased its position in shares of Exelixis by 4.9% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 1,019,297 shares of the biotechnology company’s stock worth $21,936,000 after purchasing an additional 47,730 shares during the last quarter. Finally, Marshall Wace LLP bought a new stake in shares of Exelixis in the 2nd quarter worth about $16,747,000. 79.37% of the stock is owned by institutional investors.

TRADEMARK VIOLATION WARNING: “Insider Selling: Exelixis, Inc. (EXEL) EVP Sells 14,818 Shares of Stock” was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this report on another publication, it was copied illegally and republished in violation of international copyright and trademark laws. The legal version of this report can be viewed at https://www.com-unik.info/2018/12/02/insider-selling-exelixis-inc-exel-evp-sells-14818-shares-of-stock.html.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Featured Story: What is the NASDAQ?

Insider Buying and Selling by Quarter for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit